NICE U-turns over Entyvio in Crohn's disease
This article was originally published in Scrip
Executive Summary
NICE has changed its mind over vedolizumab (Takeda's Entyvio) in Crohn's disease. Having refused to recommend it in earlier draft guidance as the evidence for the drug was "too uncertain," the HTA body for England and Wales is now recommending it be available on the NHS in final draft guidance.